Clinica Medica "A. Murri", Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy.
Eur J Clin Invest. 2022 Jul;52(7):e13768. doi: 10.1111/eci.13768. Epub 2022 Mar 26.
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with reduced bacterial diversity, altered Firmicutes/Bacteroidetes ratio, a relative abundance of alcohol-producing bacteria, or other specific genera. Changes can promote disrupted intestinal barrier and hyperpermeability, filtration of bacterial products, activation of the immune system, and pro-inflammatory changes in the intestine, in the liver, and at a systemic level. Microbiota-derived molecules can contribute to the steatogenic effects. The link between gut dysbiosis and NAFLD, however, is confused by several factors which include age, BMI, comorbidities, dietary components, and lifestyle. The role of toxic chemicals in food and water requires further studies in both gut dysbiosis and NAFLD. We can anticipate that gut microbiota manipulation will represent a potential therapeutic tool to delay or reverse the progression of NAFLD, paving the way to primary prevention measures.
非酒精性脂肪性肝病(NAFLD)是全球最常见的肝脏疾病。肠道微生物群在 NAFLD 的发病机制中起作用,因为肠道菌群失调与细菌多样性减少、厚壁菌门/拟杆菌门比值改变、产酒精细菌相对丰度或其他特定属增加有关。这些变化可促进肠道屏障破坏和通透性增加、细菌产物滤过、免疫系统激活以及肠道、肝脏和全身的促炎变化。微生物群衍生的分子可能有助于产生脂肪变性作用。然而,肠道菌群失调与 NAFLD 之间的联系受到多种因素的干扰,包括年龄、BMI、合并症、饮食成分和生活方式。食物和水中的有毒化学物质在肠道菌群失调和 NAFLD 中的作用需要进一步研究。我们可以预期,肠道微生物群的操纵将代表一种潜在的治疗工具,以延缓或逆转 NAFLD 的进展,为初级预防措施铺平道路。